ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Pear Therapeutics to Participate in the BTIG Digital Health Forum

November 8, 2021 GMT

BOSTON--(BUSINESS WIRE)--Nov 8, 2021--

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced management’s participation in the virtual BTIG Digital Health Forum being held on Monday, November 15.

Corey McCann, M.D., Ph.D., President and CEO, will participate in a panel discussion at 2:00 p.m. ET. The panel, “Setting the Pace: Commercializing Prescription Digital Therapeutics (PDTs) and Expanding the Pipeline,” will be moderated by Marie Thibault, BTIG Medical Technology and Digital Health Analyst.

ADVERTISEMENT

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET ®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O ®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst ®, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211108006080/en/

CONTACT: Media and Investors:

Meara Murphy

ADVERTISEMENT

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH TECHNOLOGY SOFTWARE GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Pear Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 11/08/2021 04:05 PM/DISC: 11/08/2021 04:06 PM

http://www.businesswire.com/news/home/20211108006080/en